TA
TARS.US Tarsus Pharmaceuticals Inc
- Market cap
- USD 3.86B
- P/E
- -
- P/B
- 37.29x
- ROE
- -889.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TARS.US undervalued?
Graham numberThe Graham number of Tarsus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tarsus Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Tarsus Pharmaceuticals Inc yet.
Tarsus Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The compa…
Full company profileTarsus Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tarsus Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 33.4M | 57.0M | 25.8M | 17.4M | 183M | 451M | 707M |
| Gross Profit | -1.00K | -74.0K | -246K | 55.0M | 24.9M | 15.9M | 170M | 421M | 660M |
| Operating Income | -1.35M | -4.30M | -27.0M | -12.2M | -62.7M | -143M | -121M | -71.0M | -917M |
| EBITDA | -1.32M | -4.56M | -26.7M | -13.5M | -59.7M | -132M | -106M | -53.6M | -907M |
| Net Income | -1.32M | -4.67M | -26.8M | -13.8M | -62.1M | -136M | -116M | -66.4M | -925M |
| EPS | -0.31 | -0.24 | -1.32 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -20 |
| Balance Sheet | |||||||||
| Total Assets | 2.39M | 58.3M | 172M | 179M | 228M | 265M | 377M | 562M | 505M |
| Total Liabilities | 3.74M | 64.3M | 5.99M | 12.2M | 35.0M | 68.5M | 152M | 219M | 401M |
| Shareholders' Equity | -1.35M | -6.01M | 166M | 167M | 193M | 197M | 225M | 343M | 104M |
| Cash & Short-term Investments | 2.36M | 58.0M | 168M | 172M | 217M | 227M | 291M | 417M | 310M |
| Total Debt | - | 164K | 831K | 1.89M | 20.2M | 30.2M | 72.5M | 93.6M | 88.7M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.18M | -3.67M | -21.1M | 3.75M | -49.0M | -117M | -83.0M | -12.5M | 48.2M |
| Capital Expenditure | 7.00K | 175K | 456K | 586K | 506K | 5.50M | 1.57M | 9.86M | 14.8M |
| Free Cash Flow | -1.19M | -3.85M | -21.6M | 3.16M | -49.5M | -123M | -84.6M | -22.3M | 33.4M |
| Ratios | |||||||||
| ROE | - | - | -16.2% | -8.3% | -32.2% | -69.0% | -51.5% | -19.3% | -889.3% |
| ROA | -55.2% | -8.0% | -15.6% | -7.7% | -27.2% | -51.2% | -30.7% | -11.8% | -183.0% |
| Net Profit Margin | - | - | -80.2% | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% | -130.8% |
| Debt to Equity | - | - | 0.01x | 0.01x | 0.10x | 0.15x | 0.32x | 0.27x | 0.85x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tarsus Pharmaceuticals Inc dividends
Tarsus Pharmaceuticals Inc has not paid dividends in the last 8 fiscal years.
Who owns Tarsus Pharmaceuticals Inc
- Insiders 2.69%
- Institutions 97.31%
- Public & others 0.00%
- Shares outstanding 49.3M
- Free float 38.1M
Top funds holding TARS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.40M | 2.84% | +7.60% | Sep 2026 |
| First Trust NYSE Arca Biotech ETF | 1.34M | 2.71% | 0.00% | Oct 2026 |
| iShares Russell 2000 ETF | 1.06M | 2.15% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 459K | 0.93% | +0.15% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 409K | 0.83% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 399K | 0.81% | +14.92% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 393K | 0.80% | -0.38% | Oct 2026 |
| Janus Henderson Glb Life Scn I2 USD | 391K | 0.79% | +13.13% | Aug 2026 |
| Fidelity Small Cap Growth | 375K | 0.76% | 0.00% | Aug 2026 |
| PGIM Jennison Small Company A | 372K | 0.75% | -8.88% | Sep 2026 |
| iShares Biotechnology ETF | 363K | 0.74% | +12.73% | Oct 2026 |
| Fidelity Select Health Care | 360K | 0.73% | 0.00% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 323K | 0.65% | +9.77% | Jun 2026 |
| Janus Henderson Triton D | 284K | 0.58% | 0.00% | Sep 2026 |
| Loomis Sayles Small Cap Growth Instl | 247K | 0.50% | 0.00% | Sep 2026 |
| Invesco Pharmaceuticals ETF | 247K | 0.50% | +0.45% | Oct 2026 |
| Vanguard Russell 2000 ETF | 243K | 0.49% | +1.13% | Sep 2026 |
| ClearBridge Small Cap Growth A | 238K | 0.48% | -23.07% | Sep 2026 |
| Fidelity Growth Company Fund | 229K | 0.46% | 0.00% | Aug 2026 |
| MEDICAL BioHealth EUR Acc | 219K | 0.44% | -45.37% | Aug 2026 |
Top institutions holding TARS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 3.86M | 7.82% | +8.54% | Jun 2026 |
| Deep Track Capital, LP | 3.67M | 7.44% | +1.85% | Jun 2026 |
| RTW INVESTMENTS, LLC | 3.36M | 6.81% | +0.33% | Jun 2026 |
| Jupiter Topco LLC | 2.81M | 5.70% | 0.00% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 2.78M | 5.63% | +8.33% | Jun 2026 |
| Assenagon Asset Management SA | 1.89M | 3.84% | +48.02% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.83M | 3.71% | -6.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.79M | 3.64% | +1.85% | Jun 2026 |
| Jennison Associates LLC | 1.66M | 3.37% | -2.83% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.57M | 3.18% | +31.94% | Jun 2026 |
| Millennium Management LLC | 1.43M | 2.89% | +152.78% | Jun 2026 |
| Bank of America Corp | 1.19M | 2.42% | -0.10% | Jun 2026 |
| Geode Capital Management, LLC | 1.11M | 2.24% | -1.37% | Jun 2026 |
| State Street Corp | 1.07M | 2.18% | +9.68% | Jun 2026 |
| Vestal Point Capital LP | 1.05M | 2.13% | +425.00% | Jun 2026 |
| Amvescap Plc. | 786K | 1.59% | +5.83% | Jun 2026 |
| The Goldman Sachs Group Inc | 743K | 1.51% | +68.94% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 729K | 1.48% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 711K | 1.44% | -10.19% | Jun 2026 |
| FMR Inc | 673K | 1.36% | -8.23% | Jun 2026 |
Tarsus Pharmaceuticals Inc company profile
- Company name
- Tarsus Pharmaceuticals Inc
- Ticker
- TARS.US
- Exchange
- USA Stocks
- Listed since
- Oct 16, 2020
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 370
- Fiscal year end
- December
- Address
- 17700 Laguna Canyon Road, Irvine, CA, United States, 92618
- Phone
- 949 418 1801
- Website
- tarsusrx.com
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals Inc management
10- Dr. Bobak R. Azamian M.D.Co-Founder, President, CEO & Chairman
- Dr. Seshadri Neervannan Ph.D.Chief Operating Officer · born 1968
- Dr. Bryan Wahl J.D., M.D.General Counsel & Corporate Secretary · born 1978
- Mr. David NakasoneHead of Investor Relations
- Ms. Adrienne KempVice President of Corporate Communications
- Mr. Matthew Rossen M.B.A.Vice President of Marketing · born 1978
- Mr. Scott YoumansVice President of Sales
- Ms. Dianne C. Whitfield M.S.W.Chief Human Resources Officer · born 1977
- Dr. Elizabeth Yeu-Lin M.D.Chief Medical Officer · born 1978
- Ms. Cara MillerSenior Vice President of Corporate Affairs